This section contains information about clinical trials that are recruiting people with MS. This information has been provided to us by the investigators involved, and although we try to keep it current, it is possible that the trials are no longer enrolling patients.
Individuals who are interested in participating in a clinical trial are encouraged to discuss the possibility with their personal physician.
MS Centers Recruiting Subjects in Washington
Below is a listing of other clinical trials that we are aware of that are recruiting subjects in our community:
Aging with a Physical Disability Survey Study
It may be surprising to you, but rehabilitation professionals don’t know much about the natural course of aging with physical disabilities. The University of Washington Aging Rehabilitation Research and Training Center is recruiting people who live with multiple sclerosis, muscular dystrophy, post-polio syndrome and spinal cord injury to participate in a survey to learn how aging impacts life with a disability, and what to expect long term as a person with a physical disability ages. Download the information sheet
If you decide to participate in this study, you will be asked to fill out two to four surveys over the course of four years, depending on your age. As long as you are over 18, you are eligible to participate.
If you would like to participate, please contact UW project staff at:
University of Washington
Aging Rehabilitation Research and Training Center
Department of Rehabilitation Medicine
206-221-5641 or 1-866-928-2114
agerrtc@u.washington.edu*
* Please remember that we cannot guarantee the confidentiality of any information sent by email.
Veterans Administration - Cognition Study
The VA is currently recruiting veteran and non-veteran patients with Multiple Sclerosis (MS) (relapsing remitting or secondary progressive types only) for a cognition study. We are evaluating the effectiveness of an herbal supplement, Ginkgo bilboa, on cognitive impairment.
We are looking for people between 18-60 years old who are native English speakers, have not used Ginkgo bilboa for the past 30 days, and who have no significant medical problems. You cannot have had a MS relapse within 6 months of entering the program. Participants will need to be willing to come to the Seattle VA three times for assessments during the 6 months of the study.
For further information, please contact Jim Hunziker, ARNP, Study Coordinator at 206-277-5519, or 1-800-329-8387 x65519.
Studying factors that may lead to promoting health and wellness
A young investigator is seeking to recruit 200 adults with MS to respond to an online survey about health actions, disease activity, quality of life and life satisfaction. Chung-Yi Chiu, a PhD candidate in the Department of Rehabilitation Psychology and Special Education at the University of Wisconsin-Madison, is conducting the study to understand the factors that contribute to health promotion in people with MS, to help plan effective and efficient interventions that can improve health and wellness in people with MS.
Participation is voluntary and information gathered is anonymous and will be kept confidential. The survey will take an estimated 30-45 minutes to complete.
The survey is available online at mshealthsurvey.blogspot.com. For questions and comments contact Dr. Chiu at cchiu3@wisc.edu.
Integrity Medical Research - Dignity Study
Is an overactive bladder causing you to live an underactive life?
If you have been diagnosed with multiple sclerosis or have a spinal cord injury,and suffer from incontinence resulting from an overactive bladder, we invite you to find out if you qualify for the Dignity Study. The purpose of the study is to determine the effectiveness and safety of an investigational medication for controlling symptoms of overactive bladder in patients with these conditions. Physicians in your area are conducting the Dignity Study. Investigational study medication, medical exams, and lab tests will be provided to you at no charge.
To learn more and determine if you may qualify to participate, email anavarrete@integritymedresearch.com, call 1-888-61-STUDY (1-888-617-8839) or visit DignityStudy.com.
MS Center at Evergreen, Kirkland
Do you have daily pain from your MS? The MS Center at Evergreen is enrolling participants for a research trail for MS-related pain. The study will evaluate whether an oral investigational medication is effective to relieve MS-related nerve pain when compared to placebo. The trail will last approximately 10 weeks and requires 3 clinic visits. The research evaluation will be offered to you free of charge and a stipend will be provided to help with travel expenses. Participants must have MS and daily pain for three months or more. If you are interested to learn more about the study, please contact: Jennifer McAlleenan, MS Center at Evergreen: 425-899-5371.
RTL1000
RTL1000 is an investigational drug that is thought to have a highly targeted action in animal model of Multiple Sclerosis.
This study is to evaluate the safety profile of RTL1000 when administered by intravenous infusion. Medication will be given only once and it is unlikely to benefit the subject. To be eligible for this study:
- Have definite diagnosis of RRMS or SPMS.
- 18 to 65 years old.
- Able to walk with a cane or crutches at least 32 feet without resting.
For more information, please contact Yuriko Courtney, Lead Research Coordinator at MS Center at Evergreen: 425-899-5370.
FTY 720 22309
MS Center at Evergreen is currently enrolling individuals with a diagnosis of Multiple Sclerosis in the “FTY 720” research study. This study will evaluate the safety and effectiveness of Fingolimod (FTY 720), an investigational oral medication for treatment of MS. We are looking for people with active Relapsing-Remitting Multiple Sclerosis. This study medication can NOT be taken with interferon β products (Avonex® Betaseron®, Rebif®) or Glatiramer Acetate (Copaxone®). In this 24 month study, one third of participants will receive 1.25mg of Fingolimod, another third will receive 0.5mg of Fingolimod and one third will receive placebo (pill with no active ingredients). If you are interested in learning more about this study, please call Yuriko Courtney at 425-899-5370.
Ambulation study
The MS Center at Evergreen is looking for MS patients with walking problems. We are trying to find out which clinical tests of walking and balance best predict walking problems due to MS. The study involves three study visits over a period of 6 months. Please contact Jan Sorenson at 425-899-5361.
Memantine in Memory
The MS Center at Evergreen is currently enrolling MS patients into a clinical research trial of Memantine/Placebo. We are looking to see if Memantine is effective in improving cognitive function with patients with multiple sclerosis. The study involves three visits over a period of 16 weeks. People who would like to address their memory problems are encouraged to participate. Please contact Kathleen Butler at 425-899-5373.
CombinRX
The MS Center at Evergreen is currently enrolling MS patients into a clinical trial of combination therapy with Avonex and Copaxone. Everyone receive either Avonex, Copaxone or both. The study involves 15 visits over a period of 36 months. We are looking for people with Relapsing Remitting MS who have never treated with disease modifying medication. Please contact Shalom Kilcup at 425-899-3569.
Maestro study
MS Center at Evergreen is currently looking for adults who have been diagnosed with secondary progressive Multiple Sclerosis (SPMS) to participate in a clinical research study evaluating the safety and effectiveness of an investigational SPMS medication when compared to a placebo. The study will last up to 3 years and require at least 11 visits to the clinic. All the study related medical evaluations and investigational medication will be provided at no cost. Additionally, a small sum will be paid to compensate for travel. If you are interested and would like to hear more about the study, please call Shalom Kilcup at 425-899-5369.
Duloxetine
The MS Center at Evergreen is enrolling individuals into a clinical trial of an investigational pain medication Duloxetine. In this research study, we will investigate whether Duloxetine is effective and safe to treat people with MS related pain. 50% of the participants will receive active medication and 50% will receive placebo.
The trial will last approximately 10 weeks and require 3 clinic visits. Study medication and procedures will be supplied to you free of charge.
Eligible participants will have definite diagnosis of MS who have chronic MS related pain. If you are interested to learn more about this study, please contact our research coordinator: Jennifer McAleenan, MS Center at Evergreen Healthcare, at 425-899-5371.